Strengthening the EU's
pandemic preparedness











ABOUT EVAMOBS
A novel platform to develop antivirals
EvaMobs is taking a new approach in antiviral development, by using evolvable monobodies, or “Mobs” for short.
Mobs are small proteins that can be tailored to have a high affinity for any type of virus. In other words, by making specific changes to the framework of Mobs, this technology can be used to easily generate specific molecules that can “attack” and inactivate a particular virus.
Using evolvable and rapidly adaptable Mobs in combination with computational tools, EvaMobs is creating an innovative platform for the rapid development of new antiviral drugs.
A monobody (in pink) tightly bound to the
SARS-COV-2 receptor binding domain (in blue)
IN A NUTSHELL
EvaMobs under 2 minutes
Curious about a quick overview of the EvaMobs project? Watch our project video!
ABOUT EVAMOBS
Our research steps
Discovery of new
Mobs
With a computational framework, millions of computer-designed Mobs will be discovered, and characterised.
Production of
specific Mobs
A narrowed down selection of discovered Mobs will be produced.
Preclinical
validation
The Mobs will undergo testing of the safety, efficacy and the dosage in preclinical models.
Phase 1 clinical
validation
The most promising Mob will be tested for safe use in humans.
![]()
Discovery of
new Mobs
With a computational framework, millions of computer-designed Mobs will be discovered, and characterised.
![]()
Production of
specific Mobs
A narrowed down selection of discovered Mobs will be produced.
![]()
Preclinical
validation
The Mobs will undergo testing of the safety, efficacy and the dosage in preclinical models.
![]()
Phase 1
clinical validation
The most promising Mob will be tested for safe use in humans.
OUR LATEST UPDATES
News

EvaMobs presented at Croatia’s National Information Day on Horizon Europe
Maja Katalinić presented the EvaMobs project during Croatia’s National Information Day dedicated to Horizon Europe Cluster 1 Health and the Cancer Mission.

Collaborating across Europe: Neha’s secondment at ITQB NOVA
To truly understand how stability of the monobodies links to earlier development steps, Neha Dalvi from NIBRT recently travelled to ITQB NOVA for a secondment.

Collaborating across Europe: Arda’s secondment at ITQB NOVA
Recently, Arda Deniz Tugrul, PhD candidate at NIBRT (UCD) in Dublin travelled to ITQB NOVA for a six-week secondment.
WORK WITH US
Job offers
Postdoc Position - CNB-CSIC
Three-dimensional reconstruction, using cryo-EM data, of complexes between different viral receptors and synthetic antiviral proteins
There are currently no job offers available
Postdoc Position - IMROH, Zagreb, Croatia
Initial assessment of monobodies' (Mobs) effects on human cells
TEAM
Our partners
EvaMobs is a consortium consisting of 11 European partners, coordinated by ITQB NOVA, NOVA University of Lisbon.











OUR RESULTS
Activities and Outputs
Find our communication activities, publications and other outputs.

